POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as Part of ...
BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a
Source: kentuckytoday.com